Cargando…

Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort

The aim of this study was to evaluate whether the presence of anti-hepatitis B (HBV) c antibodies (HBcAb positivity) could influence the control of HIV viremia in patients living with HIV (PLWH) who switch to two-drug antiretroviral therapy (2DR) containing lamivudine (3TC) (2DR-3TC-based). A retros...

Descripción completa

Detalles Bibliográficos
Autores principales: Malagnino, Vincenzo, Salpini, Romina, Teti, Elisabetta, Compagno, Mirko, Ferrari, Ludovica, Mulas, Tiziana, Svicher, Valentina, Zordan, Marta, Basso, Monica, Battagin, Giuliana, Panese, Sandro, Rossi, Maria Cristina, Scaggiante, Renzo, Zago, Daniela, Iannetta, Marco, Parisi, Saverio Giuseppe, Andreoni, Massimo, Sarmati, Loredana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860946/
https://www.ncbi.nlm.nih.gov/pubmed/36680233
http://dx.doi.org/10.3390/v15010193
_version_ 1784874718321442816
author Malagnino, Vincenzo
Salpini, Romina
Teti, Elisabetta
Compagno, Mirko
Ferrari, Ludovica
Mulas, Tiziana
Svicher, Valentina
Zordan, Marta
Basso, Monica
Battagin, Giuliana
Panese, Sandro
Rossi, Maria Cristina
Scaggiante, Renzo
Zago, Daniela
Iannetta, Marco
Parisi, Saverio Giuseppe
Andreoni, Massimo
Sarmati, Loredana
author_facet Malagnino, Vincenzo
Salpini, Romina
Teti, Elisabetta
Compagno, Mirko
Ferrari, Ludovica
Mulas, Tiziana
Svicher, Valentina
Zordan, Marta
Basso, Monica
Battagin, Giuliana
Panese, Sandro
Rossi, Maria Cristina
Scaggiante, Renzo
Zago, Daniela
Iannetta, Marco
Parisi, Saverio Giuseppe
Andreoni, Massimo
Sarmati, Loredana
author_sort Malagnino, Vincenzo
collection PubMed
description The aim of this study was to evaluate whether the presence of anti-hepatitis B (HBV) c antibodies (HBcAb positivity) could influence the control of HIV viremia in patients living with HIV (PLWH) who switch to two-drug antiretroviral therapy (2DR) containing lamivudine (3TC) (2DR-3TC-based). A retrospective multicentre observational study was conducted on 160 PLWH switching to the 2DR-3TC-based regimen: 51 HBcAb-positive and 109 HBcAb-negative patients. The HBcAb-positive PLWH group demonstrated a significantly lower percentage of subjects with HIV viral suppression with target not detected (TND) at all time points after switching (24th month: 64.7% vs. 87.8%, p < 0.0001; 36th month 62.7% vs. 86.8%, p = 0.011; 48th month 57.2% vs. 86.1%, p = 0.021 of the HBcAb-positive and HBcAb-negative groups, respectively). Logistic regression analysis showed that the presence of HBcAb positivity (OR 7.46 [95% CI 2.35–14.77], p = 0.004) could favour the emergence of HIV viral rebound by nearly 54% during the entire study follow-up after switching to 2DR-3TC.
format Online
Article
Text
id pubmed-9860946
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98609462023-01-22 Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort Malagnino, Vincenzo Salpini, Romina Teti, Elisabetta Compagno, Mirko Ferrari, Ludovica Mulas, Tiziana Svicher, Valentina Zordan, Marta Basso, Monica Battagin, Giuliana Panese, Sandro Rossi, Maria Cristina Scaggiante, Renzo Zago, Daniela Iannetta, Marco Parisi, Saverio Giuseppe Andreoni, Massimo Sarmati, Loredana Viruses Article The aim of this study was to evaluate whether the presence of anti-hepatitis B (HBV) c antibodies (HBcAb positivity) could influence the control of HIV viremia in patients living with HIV (PLWH) who switch to two-drug antiretroviral therapy (2DR) containing lamivudine (3TC) (2DR-3TC-based). A retrospective multicentre observational study was conducted on 160 PLWH switching to the 2DR-3TC-based regimen: 51 HBcAb-positive and 109 HBcAb-negative patients. The HBcAb-positive PLWH group demonstrated a significantly lower percentage of subjects with HIV viral suppression with target not detected (TND) at all time points after switching (24th month: 64.7% vs. 87.8%, p < 0.0001; 36th month 62.7% vs. 86.8%, p = 0.011; 48th month 57.2% vs. 86.1%, p = 0.021 of the HBcAb-positive and HBcAb-negative groups, respectively). Logistic regression analysis showed that the presence of HBcAb positivity (OR 7.46 [95% CI 2.35–14.77], p = 0.004) could favour the emergence of HIV viral rebound by nearly 54% during the entire study follow-up after switching to 2DR-3TC. MDPI 2023-01-10 /pmc/articles/PMC9860946/ /pubmed/36680233 http://dx.doi.org/10.3390/v15010193 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Malagnino, Vincenzo
Salpini, Romina
Teti, Elisabetta
Compagno, Mirko
Ferrari, Ludovica
Mulas, Tiziana
Svicher, Valentina
Zordan, Marta
Basso, Monica
Battagin, Giuliana
Panese, Sandro
Rossi, Maria Cristina
Scaggiante, Renzo
Zago, Daniela
Iannetta, Marco
Parisi, Saverio Giuseppe
Andreoni, Massimo
Sarmati, Loredana
Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort
title Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort
title_full Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort
title_fullStr Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort
title_full_unstemmed Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort
title_short Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort
title_sort role of hbcab positivity in increase of hiv-rna detectability after switching to a two-drug regimen lamivudine-based (2dr-3tc-based) treatment: months 48 results of a multicenter italian cohort
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860946/
https://www.ncbi.nlm.nih.gov/pubmed/36680233
http://dx.doi.org/10.3390/v15010193
work_keys_str_mv AT malagninovincenzo roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort
AT salpiniromina roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort
AT tetielisabetta roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort
AT compagnomirko roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort
AT ferrariludovica roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort
AT mulastiziana roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort
AT svichervalentina roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort
AT zordanmarta roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort
AT bassomonica roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort
AT battagingiuliana roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort
AT panesesandro roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort
AT rossimariacristina roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort
AT scaggianterenzo roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort
AT zagodaniela roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort
AT iannettamarco roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort
AT parisisaveriogiuseppe roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort
AT andreonimassimo roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort
AT sarmatiloredana roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort